KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Cash Flow (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Net Cash Flow for 6 consecutive years, with $84.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 50.38% year-over-year to $84.7 million, compared with a TTM value of $132.9 million through Dec 2025, down 35.2%, and an annual FY2025 reading of $132.9 million, down 35.2% over the prior year.
  • Net Cash Flow was $84.7 million for Q4 2025 at Recursion Pharmaceuticals, down from $131.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $423.8 million in Q2 2021 and bottomed at -$238.0 million in Q3 2021.
  • Average Net Cash Flow over 5 years is $23.6 million, with a median of -$9.4 million recorded in 2022.
  • The sharpest move saw Net Cash Flow crashed 2600.26% in 2023, then surged 4068.66% in 2024.
  • Year by year, Net Cash Flow stood at -$109.6 million in 2021, then surged by 186.25% to $94.5 million in 2022, then tumbled by 95.67% to $4.1 million in 2023, then soared by 4068.66% to $170.7 million in 2024, then crashed by 50.38% to $84.7 million in 2025.
  • Business Quant data shows Net Cash Flow for RXRX at $84.7 million in Q4 2025, $131.4 million in Q3 2025, and $15.4 million in Q2 2025.